The trajectory of companies tied to Sildenafil's legacy presents a intricate investment picture . While the initial success generated substantial returns , generic copies have significantly diminished sales . Investing in associated pharmaceutical businesses now requires a careful assessment of proprietary safeguards, evolving healthcare changes, a